Actively Recruiting

Phase 2
Age: 50Years - 99Years
All Genders
NCT04504123

MMP-9 Inhibition for Recalcitrant Wet AMD

Led by University of Iowa · Updated on 2026-04-02

50

Participants Needed

1

Research Sites

329 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world. Currently, anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVI) remain the standard-of-care treatment for wAMD. Previous studies show that about 90% of treated patients lose minimal visual function after 2 years of follow-up. There is still, a subset of 15% patients, incomplete responders, that do not improve and possibly worsen due to the persistence of sub-retinal fluid (with or without intra-retinal fluid) with chronic treatment. The investigators plan to evaluate the effect of oral doxycycline versus placebo on the anatomic and functional outcomes in persistent sub-retinal eye fluid in neovascular wet age-related macular degeneration. This subset are incomplete or non-responders to current anti-VEGF intravitreal therapy.

CONDITIONS

Official Title

MMP-9 Inhibition for Recalcitrant Wet AMD

Who Can Participate

Age: 50Years - 99Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of wet age-related macular degeneration (wAMD)
  • Treated only with anti-VEGF intravitreal injections for active choroidal neovascularization due to wAMD
  • Can have other retinal conditions like diabetic retinopathy or vein occlusion if not treated with anti-VEGF injections
  • Must have persistent sub-retinal and/or intra-retinal fluid due to active wAMD despite at least three consecutive anti-VEGF injections
  • No previous side effects from tetracycline medications
Not Eligible

You will not qualify if you...

  • History of uveitis or intraocular inflammation
  • Significant epiretinal membrane or macular hole distorting macular anatomy
  • Media opacity preventing fluid detection on OCT
  • Eye surgery within 3 months prior, or planned surgery within 9 months following randomization
  • Peribulbar corticosteroid injection within past 6 months
  • Intravitreal triamcinolone injection within past 4 months
  • Other ocular conditions affecting vision during study (e.g., retinal vein occlusion, uveitis, neovascular glaucoma)
  • Choroidal neovascularization from causes other than wAMD
  • Inability to attend 6- and 9-month follow-ups
  • Missing two or more consecutive anti-VEGF injections during 6-month treatment
  • Need for imminent change in anti-VEGF medication or other treatments during study
  • Fluid associated with geographic atrophy or disciform scar
  • Sub-retinal or intra-retinal fluid not caused by choroidal neovascularization
  • Active treatment for Irvine-Gass Syndrome
  • Unstable medical condition affecting ability to complete 9-month study
  • Significant kidney disease (serum creatinine >2.5 mg/dL)
  • Very high blood pressure (systolic >180 mm Hg or diastolic >110 mm Hg)
  • History of headaches related to tetracycline use
  • History of pseudotumor cerebri
  • Tetracycline use within past 6 months
  • Pregnancy or planning pregnancy during study
  • Sexually active women of child-bearing potential not using effective birth control
  • Known allergy or intolerance to doxycycline or related drugs
  • Use of certain medications (phenytoin, barbiturates, carbamazepine, digoxin, isotretinoin)
  • History of gastroparesis, gastrectomy, or gastric bypass
  • Use of strontium, acitretin, or tretinoin
  • Abnormal liver enzymes (ALT or AST) at baseline

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Iowa Hospitals & Clinics Department of Ophthalmology & Visual Sciences

Iowa City, Iowa, United States, 52242

Actively Recruiting

Loading map...

Research Team

E

Elliott H Sohn, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

MMP-9 Inhibition for Recalcitrant Wet AMD | DecenTrialz